Article
Oncology
Hans Raskov, Adile Orhan, Ali Salanti, Shruti Gaggar, Ismail Gogenur
Summary: NK cells play a crucial role in cancer treatment by recognizing and killing transformed cells, potentially improving treatment outcomes. Current research focuses on the development of immunotherapeutic approaches, including immune checkpoint inhibitors and adoptive cell transfer using T cells with chimeric antigen receptors to enhance immune function.
Review
Biochemistry & Molecular Biology
Tatiana Michel, Markus Ollert, Jacques Zimmer
Summary: Despite the challenges in cancer treatment, immunotherapy based on NK cells is considered to be one of the most promising options and has already shown success in clinical settings. This review highlights the different possibilities and mechanisms of NK cells in cancer therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Erin E. Peterson, Kevin C. Barry
Summary: The intercellular cross-talk between NK cells and cDC1s plays a crucial role in immune responses to cancer, impacting the efficacy of certain immunotherapies and overall survival rates for patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Seung Hee Choi, Hye Jin Kim, Joo Dong Park, Eun-Su Ko, Minwook Lee, Dae-Keum Lee, Jin-Ho Choi, Hye Jung Jang, Isaac Kim, Hae-Yun Jung, Keun-Hong Park, Kyung-Soon Park
Summary: The chemical priming of NK cells using 25KbPEI enhances their antitumor activity and migration ability, offering a simple and cost-effective method for producing therapeutic NK cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Sainiteesh Maddineni, John L. Silberstein, John B. Sunwoo
Summary: This article reviews multiple approaches for allogeneic NK cell therapy and discusses the advantages and disadvantages of each method. In recent years, NK cells have become increasingly important players in the immune response against cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Oleksandr Kyrysyuk, Kai W. Wucherpfennig
Summary: T cells and NK cells have complementary roles in tumor immunity. Targeting immune evasion mechanisms and shared receptors between T cells and NK cells can enhance their immune response. Inhibitory and activating cytokines are also potential therapeutic strategies to impact lymphocyte function in tumors.
ANNUAL REVIEW OF IMMUNOLOGY
(2023)
Article
Oncology
Xuan Guo, Tanel Mahlakoiv, Qian Ye, Srinivas Somanchi, Shuyang He, Hemlata Rana, Andrea DiFiglia, Joseph Gleason, William van der Touw, Robert Hariri, Xiaokui Zhang
Summary: The study successfully achieved 94% knockout efficiency of CBLB using CRISPR/Cas9 technology in placental CD34(+) cells, demonstrating the negative regulatory role of CBLB in PNK cell cytotoxicity against tumor cells. Ablation of CBLB did not impact PNK cell proliferation, differentiation, or phenotypical characteristics, but resulted in enhanced cytotoxicity against tumor cells. Furthermore, CBLB knockout PNK cells showed increased in vivo proliferation, maturation, and antitumor activity compared to unmodified PNK cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Virender Kumar, Ram I. Mahato
Summary: This article discusses various approaches to enhance NK cell functions for the treatment of pancreatic cancer, as well as new advances in boosting NK cell therapeutic efficacy using nanoparticle mediation.
Article
Oncology
Jiacheng Bi, Chen Huang, Xiaomeng Jin, Chaoyue Zheng, Yingying Huang, Xiaohu Zheng, Zhigang Tian, Haoyu Sun
Summary: By analyzing single-cell transcriptomics and using gene reporter mice, this study found that TIPE2 expression correlated with NK cell exhaustion in the tumor microenvironment (TME) in both humans and mice. Deletion of TIPE2 improved the antitumor activity of adoptively transferred mouse NK cells and human NK cells, either derived from peripheral blood or induced pluripotent stem cells (iPSCs). Additionally, TIPE2 deletion synergized with CISH deletion to further enhance antitumor activity in vivo.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Immunology
Cristina Zalfa, Silke Paust
Summary: In the tumor microenvironment, myeloid-derived suppressor cells play a crucial role in regulating NK cell function, impacting the antitumor immune response. Strategies targeting MDSC-mediated immunosuppression can enhance the cytotoxic antitumor activity of NK cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Xiaobo Peng, Ling Chen, Yuan Jiao, Yujie Wang, Zhibin Hao, Xianbao Zhan
Summary: Pancreatic cancer is a highly malignant disease with poor prognosis, but immunotherapy using NK cells offers new hope. NK cells play a key role in immune surveillance and have potential applications in the treatment of pancreatic cancer.
Article
Oncology
Nadine Landolina, Francesca Romana Mariotti, Tiziano Ingegnere, Claudia Alicata, Biancamaria Ricci, Andrea Pelosi, Irene Veneziani, Bruno Giuseppe Azzarone, Cecilia Garlanda, Alberto Mantovani, Lorenzo Moretta, Enrico Maggi
Summary: This study aimed to investigate the role of IL-1R8 in human NK cells and optimize its silencing conditions. The results showed that silencing IL-1R8 can enhance the activity and anti-tumor response of NK cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Sarah Nersesian, Emily B. Carter, Stacey N. Lee, Lauren P. Westhaver, Jeanette E. Boudreau
Summary: NK cells integrate heterogeneous signals for activation and inhibition using germline-encoded receptors, which may be key to comprehensive cancer control. Strategies to leverage their naturally occurring diversity and agility have not yet been developed. Their receptors and signaling pathways play important roles in cancer and potential as targets for immunotherapies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Nicky A. Beelen, Merel R. Aberle, Virginia Bruno, Steven W. M. Olde Damink, Gerard M. J. Bos, Sander S. Rensen, Lotte Wieten
Summary: This study evaluated the cytotoxic potential of adoptive NK cells against pancreatic cancer organoids and found that ADCC-inducing antibodies can enhance NK cell anti-tumor responses.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Engineering, Biomedical
Zhenghu Chen, Zihua Zeng, Quanyuan Wan, Xiaohui Liu, Jianjun Qi, Youli Zu
Summary: This study demonstrates a novel immunotherapeutic approach for targeting triple-negative breast cancer (TNBC) using aptamer-engineered NK cells. The synthetic aptamer probes selectively target TNBC cell lines and trigger apoptosis and death of cultured TNBC cells. Systemic administration of aptamer-engineered NK cells inhibits lung metastasis in mice harboring TNBC xenografts.
Article
Oncology
Lacy E. Lowry, Joshua L. Fenderson, Russell A. Baur
JOURNAL OF ONCOLOGY PRACTICE
(2019)
Article
Medicine, General & Internal
Kandamurugu Manickam, Adam H. Buchanan, Marci L. B. Schwartz, Miranda L. G. Hallquist, Janet L. Williams, Alanna Kulchak Rahm, Heather Rocha, Juliann M. Savatt, Alyson E. Evans, Loren M. Butry, Amanda L. Lazzeri, D'Andra M. Lindbuchler, Carroll N. Flansburg, Rosemary Leeming, Vitor G. Vogel, Matthew S. Lebo, Heather M. Mason-Suares, Derick C. Hoskinson, Noura S. Abul-Husn, Frederick E. Dewey, John D. Overton, Jeffrey G. Reid, Aris Baras, Huntington F. Willard, Cara Z. McCormick, Sarath B. Krishnamurthy, Dustin N. Hartzel, Korey A. Kost, Daniel R. Lavage, Amy C. Sturm, Lauren R. Frisbie, T. Nate Person, Raghu P. Metpally, Monia A. Giovanni, Lacy E. Lowry, Joseph B. Leader, Marylyn D. Ritchie, David J. Carey, Anne E. Justice, H. Lester Kirchner, W. Andrew Faucett, Marc S. Williams, David H. Ledbetter, Michael F. Murray
